Lynx1 Capital Management LP 13D and 13G filings for Kinnate Biopharma Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 09:21 am Sale |
2023-12-31 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 1,997,006 4.200% |
-216,172 (-9.77%) |
Filing |
| 2023-01-23 4:28 pm Purchase |
2023-01-13 | 13G | Kinnate Biopharma Inc. KNTE |
Lynx1 Capital Management LP | 2,213,178 5.000% |
2,213,178 (New Position) |
Filing |